Search for: "Jacqueline Berman"
Results 1 - 20
of 63
Sorted by Relevance
|
Sort by Date
11 Jul 2021, 10:00 pm
Partners Jacqueline Berman and Jeffrey Gargano and and associates Zachary Miller and Maria Kalousi-Tatum published an analysis of the latest updates to the US Food and Drug Administration’s (FDA’s) Purple Book. [read post]
11 Jul 2021, 10:00 pm
Partners Jacqueline Berman and Jeffrey Gargano and and associates Zachary Miller and Maria Kalousi-Tatum published an analysis of the latest updates to the US Food and Drug Administration’s (FDA’s) Purple Book. [read post]
11 Jul 2021, 10:00 pm
Partners Jacqueline Berman and Jeffrey Gargano and and associates Zachary Miller and Maria Kalousi-Tatum published an analysis of the latest updates to the US Food and Drug Administration’s (FDA’s) Purple Book. [read post]
11 Jul 2021, 10:00 pm
Partners Jacqueline Berman and Jeffrey Gargano and and associates Zachary Miller and Maria Kalousi-Tatum published an analysis of the latest updates to the US Food and Drug Administration’s (FDA’s) Purple Book. [read post]
11 Jul 2021, 10:00 pm
Partners Jacqueline Berman and Jeffrey Gargano and and associates Zachary Miller and Maria Kalousi-Tatum published an analysis of the latest updates to the US Food and Drug Administration’s (FDA’s) Purple Book. [read post]
11 Jul 2021, 10:00 pm
Partners Jacqueline Berman and Jeffrey Gargano and and associates Zachary Miller and Maria Kalousi-Tatum published an analysis of the latest updates to the US Food and Drug Administration’s (FDA’s) Purple Book. [read post]
26 Oct 2023, 10:00 pm
Partners Jacqueline Berman and Maarika Kimbrell wrote an article for Law360 summarizing draft guidance from the US Food and Drug Administration that revises its approach to the dissemination of scientific information on unapproved uses (SIUU) of approved or cleared medical products. [read post]
17 Apr 2023, 10:00 pm
In an article for Clinical Leader , partner Jacqueline Berman and associate Angela Silva report that while many provisions of the US Congress’ FY 2023 Consolidated Appropriations Act (Omnibus) have received attention, one provision has flown under the radar. [read post]
26 Oct 2023, 10:00 pm
Partners Jacqueline Berman and Maarika Kimbrell wrote an article for Law360 summarizing draft guidance from the US Food and Drug Administration that revises its approach to the dissemination of scientific information on unapproved uses (SIUU) of approved or cleared medical products. [read post]
17 Apr 2023, 10:00 pm
In an article for Clinical Leader , partner Jacqueline Berman and associate Angela Silva report that while many provisions of the US Congress’ FY 2023 Consolidated Appropriations Act (Omnibus) have received attention, one provision has flown under the radar. [read post]
26 Oct 2023, 10:00 pm
Partners Jacqueline Berman and Maarika Kimbrell wrote an article for Law360 summarizing draft guidance from the US Food and Drug Administration that revises its approach to the dissemination of scientific information on unapproved uses (SIUU) of approved or cleared medical products. [read post]
1 Feb 2023, 10:00 pm
Partner Jacqueline Berman and associate Nikita Bhojani wrote a Law360 Expert Analysis article on how a new US Food and Drug Administration notice—which contrasts with an Eleventh Circuit ruling on orphan drug exclusivity—makes the scope of orphan drug exclusivity periods appear uncertain. [read post]
1 Feb 2023, 10:00 pm
Partner Jacqueline Berman and associate Nikita Bhojani wrote a Law360 Expert Analysis article on how a new US Food and Drug Administration notice—which contrasts with an Eleventh Circuit ruling on orphan drug exclusivity—makes the scope of orphan drug exclusivity periods appear uncertain. [read post]
26 Oct 2023, 10:00 pm
Partners Jacqueline Berman and Maarika Kimbrell wrote an article for Law360 summarizing draft guidance from the US Food and Drug Administration that revises its approach to the dissemination of scientific information on unapproved uses (SIUU) of approved or cleared medical products. [read post]
1 Feb 2023, 10:00 pm
Partner Jacqueline Berman and associate Nikita Bhojani wrote a Law360 Expert Analysis article on how a new US Food and Drug Administration notice—which contrasts with an Eleventh Circuit ruling on orphan drug exclusivity—makes the scope of orphan drug exclusivity periods appear uncertain. [read post]
2 Apr 2020, 9:00 pm
Kathleen Sanzo, Jacqueline Berman, Michele Buenafe, and Dennis Gucciardo explain the guidance in this LawFlash. [read post]
1 Feb 2023, 10:00 pm
Partner Jacqueline Berman and associate Nikita Bhojani wrote a Law360 Expert Analysis article on how a new US Food and Drug Administration notice—which contrasts with an Eleventh Circuit ruling on orphan drug exclusivity—makes the scope of orphan drug exclusivity periods appear uncertain. [read post]
1 Feb 2023, 10:00 pm
Partner Jacqueline Berman and associate Nikita Bhojani wrote a Law360 Expert Analysis article on how a new US Food and Drug Administration notice—which contrasts with an Eleventh Circuit ruling on orphan drug exclusivity—makes the scope of orphan drug exclusivity periods appear uncertain. [read post]
17 Apr 2023, 10:00 pm
In an article for Clinical Leader , partner Jacqueline Berman and associate Angela Silva report that while many provisions of the US Congress’ FY 2023 Consolidated Appropriations Act (Omnibus) have received attention, one provision has flown under the radar. [read post]
17 Apr 2023, 10:00 pm
In an article for Clinical Leader , partner Jacqueline Berman and associate Angela Silva report that while many provisions of the US Congress’ FY 2023 Consolidated Appropriations Act (Omnibus) have received attention, one provision has flown under the radar. [read post]
